On 13 April 2021, Evotec SE launched beLAB2122 in collaboration with Bristol-Myers Squibb company and five top-tier academic institutions. Mediated and supported by BioRN Life Science Cluster Rhine-Neckar, this $20 million BRIDGE brings together leading academic institutions in Southwestern Germany with the goal of efficiently advancing novel drug discovery projects.
The pandemic showed us that we need to establish safety and effectiveness across different populations for a universally effective vaccine, including China. And, following Covid-19 development, we noted an instant increase in clinical trials conducted in China. So, why exactly is China an attractive market to consider for drug development strategies?
Just a few years ago, single-cell analyses were complex and not user-friendly. Now, thanks to professionalised workflows, the technology is finding its way into the industry. European Biotechnology spoke with Dr Michael Schnall-Levin, SVP R&D, Founding Scientist, from market leader 10X Genomics about the increasing importance of capturing cell heterogeneity for biomedical research.
Cellex Group is an experienced facility worldwide for all kind of allogeneic and autologous stem cell collections and is, besides that, growing to become a complete service provider for cellular immunotherapy products. One essential area of the portfolio is Cell Community, the perfect solution for researchers in need of cell products.
Advanced therapy medicinal products (ATMPs) are booming, but ATMP formulations are still far from advanced: ATMPs either have a very short shelf life (hours to days) or require (ultra) cold storage conditions. A tailored formulation development program can remarkably improve this situation. Coriolis, an expert for biopharmaceutical research and (formulation) development, expands its ATMP development facilities to meet the increasing market demand.
Richter-Helm, a leading steadily growing Germany-based contract development and manufacturing organization (CDMO), offers excellent services in the continuously growing market of pharmaceutical biotechnology. Two additional bioreactors with capacities of 300 litres and 1,500 litres for microbial production will be added. This includes also the establishment of mid- and downstream processing and supporting utilities on a total area of about 10,000 m².
For a plant that has been used for millennia, controls on the supply of psychoactive and non-psychoactive components extracted from cannabis are relatively recent, with global regulations starting in the 20th century with the International Opium Conventions. The current, and often conflicting, regulatory landscape has focused on definitions of hemp and cannabidiol (CBD). Reference materials are critical to defining the % ?9-THC in these products.
Ultra-low freezers, or ULTs, are specialised refrige-rating equipment created to store vaccines, medicines, and samples at ultra-low temperatures. By offering storage temperatures ranging from -20°C to -86°C and energy efficiency, B Medical Systems’ ULTs create an ideal environment for the long-term storage of extremely temperature-sensitive biologicals, making its products perfect for use in laboratory or clinical environments.
The life sciences industry stepped up its pace in the last year to rapidly fill a void in the fight against COVID-19. Solis BioDyne is one of many companies that have experienced a dramatic increase in demand for its solutions during the pandemic especially for products used in COVID-19 diagnostic tests. The company knew it needed to ramp up production. And time was not on their side.
Adeno-associated viruses (AAV) have revolutionised gene therapies as safe and effective gene shuttles. The growing demand for AAV vectors now requires an industrialised process throughout pre-clinical development that involves comprehensive monitoring from production to patient to ensure safety and efficacy of the therapeutic agent and reduce cost of goods.